Protagenic Therapeutics, Inc. PTIX

PTIX Company Overview

Protagenic Therapeutics, Inc. (NASDAQ: PTIX) is a clinical-stage biotechnology company focused on developing therapeutics targeting stress-related and neuropsychiatric disorders. The company operates within the biopharmaceutical and central nervous system (CNS) therapeutics industries, with research efforts centered on peptide-based compounds designed to modulate stress-response pathways. Its primary development candidate has been PT00114, a synthetic form of a naturally occurring brain peptide known as TCAP (Teneurin C-terminal Associated Peptide), which has been studied for potential applications in anxiety, depression, post-traumatic stress disorder, and related conditions.

The company’s business model is centered on advancing proprietary drug candidates through preclinical and early-stage clinical development, supported by intellectual property protection and scientific licensing arrangements. Protagenic Therapeutics evolved from earlier biotechnology operations and transitioned toward CNS-focused therapeutics through licensing and development activities tied to TCAP-related technology. Public disclosures in SEC filings and investor materials indicate that the company remains in the development stage and has not reported commercial product revenue as of the latest publicly available reporting periods.